by admin | Dec 14, 2018 | 2018, HPV, Milestones
2A Pharma has received approval from the UK Medicines and Healthcare products Regulatory Authority and from the local Ethics Committee to proceed with a first-in-human study of 2AP01, which is being developed as broad coverage prophylactic HPV vaccine formulated...
by admin | Sep 27, 2018 | 2018, Collaboration, Funding & Investments, Head & Neck Cancer, Milestones
We are extremely pleased to announce that 2A Pharma in collaboration with partners from The Danish Technological Institute and Danish biotech company DNA Sense have been granted EUR 653,000 Eurostars funding for 2AP07, a project to develop a therapeutic head...
by admin | Aug 31, 2018 | 2018, Events
2A Pharma is very happy to announce that we will present at BIO Europe 2018. Please join us on Tuesday, 6 November 2018 at 4.30pm in room B3 (level 0).
by admin | Jun 25, 2018 | 2018, Funding & Investments, Milestones, Press Releases
2A Pharma is very pleased to announce that it has raised SEK 20 million (USD 2.2M) from existing and new investors. This funding augments the previously raised SEK 27 million (USD 3M) and will enable 2A Pharma to drive its leading vaccine candidate, 2AP01, a...
by admin | Feb 19, 2018 | 2018, Uncategorized
2A Pharma is overwhelmed by the positive responses we received from potential partners and collaborators at BIO-Europe Spring 2018. The conference was a resounding success from our perspective and we are looking forward to continuing the many exciting conversations...
Recent Comments